Wexford Capital’s Rigel Pharmaceuticals RIGL Stock Holding History

Wexford Capital’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,347	Closed	-$66.5K	–	504
2025 Q3	$66.5K	Buy	+2,347	New	+$70.2K	0.01%	277

Other funds holding RIGL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wexford Capital's RIGL Position: Q4 2025 in Review

Wexford Capital sold out of Rigel Pharmaceuticals (RIGL) in Q4 2025, closing a stake of 2,347 shares — an estimated $66.5K sold.

Wexford Capital first reported a position in RIGL in Q3 2025 and held it in 1 quarter. The position peaked at $66.5K in Q3 2025. 193 funds tracked by Wall St. Rank hold RIGL as of Q4 2025.

Wexford Capital reported no remaining Rigel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Wexford Capital sold 2,347 Rigel Pharmaceuticals shares in Q4 2025, an estimated $66.5K.
Wexford Capital first reported a position in Rigel Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Wexford Capital's Rigel Pharmaceuticals position peaked at $66.5K in Q3 2025.
193 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2025.

Based on Wexford Capital's 13F filing for Q4 2025, filed 13 Feb 2026.